整联蛋白及其在多发性骨髓瘤治疗中的应用  

Integrins and its application in the treatment of multiple myeloma

作　　者：郑东 朱明霞[1] 景红梅[1] ZHENG Dong;ZHU Mingxia;JING Hongmei(Department of Hematology,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院血液科,北京100191

出　　处：《现代肿瘤医学》2023年第6期1153-1156,共4页Journal of Modern Oncology

基　　金：北京康盟慈善基金会医学科研发展基金项目临床与基础研究专项(编号:TB211020)。

摘　　要：多发性骨髓瘤是恶性浆细胞肿瘤,尽管新药的治疗对患者的生存时间有显著改善,但部分患者仍面临复发和耐药的难题,该病仍无法治愈。整联蛋白及其配体在白细胞黏附、增殖、迁移及信号转导中发挥重要作用。近年研究发现多发性骨髓瘤细胞表面高表达整联蛋白,介导骨髓瘤细胞的黏附和迁移,导致细胞黏附介导的耐药性,提示预后不良。随着多发性骨髓瘤进入靶向治疗时代,整联蛋白在多发性骨髓瘤的治疗和预后价值得到关注,并有望成为新的治疗靶点。本文就整联蛋白在多发性骨髓瘤中的研究现状进行综述。Multiple myeloma is a malignant plasma cell tumor, despite significant improvements in survival with new drugs, some patients still face the challenges of relapse and drug resistance, and the disease remains incurable.Integrins and their ligands play important roles in leukocyte adhesion, proliferation, migration and signal transduction.Recent studies have found that integrin is highly expressed on the surface of multiple myeloma tumor cells, which mediates the adhesion and metastasis of tumor cells, leads to cell adhesion-mediated drug resistance and indicates poor prognosis.As multiple myeloma enters the era of targeted therapy, the therapeutic and prognostic value of integrins has gained attention and is expected to become a new therapeutic target in multiple myeloma.In this paper, we review the current status of research on integrins in multiple myeloma.

关 键 词：整联蛋白 多发性骨髓瘤 治疗靶点 

分 类 号：R733.3[医药卫生—肿瘤]